These findings suggest that combinatory therapy including inhibition of TNF and the target altering specific microbial communities (e.g. via probiotic therapy) may prove to be a beneficial therapeutic approach for IBD patients. The gene discussed is TNF; the disease is inflammatory bowel disease.